These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 29537453)

  • 1. Dermatophytomas in Onychomycosis: A Scoping Review of Prevalence, Diagnosis, and Treatment.
    Lipner SR; Vlahovic T; Ghannoum MA; Elewski B; Joseph WS
    J Am Podiatr Med Assoc; 2024; 114(2):. PubMed ID: 38753536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the Onychomycosis Severity Index in a Brazilian population.
    Tirico MCCP; Torezan L
    Eur J Dermatol; 2024 Feb; 34(1):51-54. PubMed ID: 38557458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, and Antifungal Activity of 3-Substituted-2(
    Campbell R; Buchbinder NW; Szwetkowski C; Zhu Y; Piedl K; Truong M; Matson JB; Santos WL; Mevers E
    ACS Med Chem Lett; 2024 Mar; 15(3):349-354. PubMed ID: 38505851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From the Test Tube to the Treatment Room: Fundamentals of Boron-containing Compounds and their Relevance to Dermatology.
    Del Rosso JQ; Plattner JJ
    J Clin Aesthet Dermatol; 2014 Feb; 7(2):13-21. PubMed ID: 24578778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bicalutamide: A potential new oral antiandrogenic drug for female pattern hair loss.
    Fernandez-Nieto D; Saceda-Corralo D; Jimenez-Cauhe J; Moreno-Arrones OM; Rodrigues-Barata R; Hermosa-Gelbard A; Vano-Galvan S
    J Am Acad Dermatol; 2020 Nov; 83(5):e355-e356. PubMed ID: 32320770
    [No Abstract]   [Full Text] [Related]  

  • 6. Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes.
    Axler E; Lipner SR
    Infect Drug Resist; 2024; 17():819-843. PubMed ID: 38463386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dermatophytomas: Clinical Overview and Treatment.
    Gupta AK; Wang T; Cooper EA
    J Fungi (Basel); 2022 Jul; 8(7):. PubMed ID: 35887497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Therapy Should Be Reserved as Second-Line Treatment of Onychomycosis: A Systematic Review of Onychomycosis Clinical Trials.
    Falotico JM; Lapides R; Lipner SR
    J Fungi (Basel); 2022 Mar; 8(3):. PubMed ID: 35330281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excellent Response of Dermatophytoma and Nail Splitting to Nail Plate Debridement Plus Topical Ciclopirox Olamine 1% Solution.
    Abdo HM
    Skin Appendage Disord; 2021 Feb; 7(2):127-130. PubMed ID: 33796559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults.
    Gupta AK; Daigle D
    Expert Rev Anti Infect Ther; 2014 Jul; 12(7):735-42. PubMed ID: 24894552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tavaborole topical solution, 5% for the treatment of toenail onychomycosis.
    Zane LT; Plattner J; Chanda S; Coronado D; Merchant T; Alley MR; Gupta AK
    Drugs Today (Barc); 2015 Oct; 51(10):599-607. PubMed ID: 26583302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical Tavaborole in the Treatment of Onychomycosis Complicated by Dermatophytoma: A Post-hoc Assessment of Phase II Subjects.
    Aly R; Winter T; Hall S; Vlahovic T
    J Drugs Dermatol; 2018 Mar; 17(3):347-354. PubMed ID: 29537453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tavaborole in Difficult-to-Treat Onychomycosis Cases: A Post-hoc Assessment of Phase III Subjects.
    Aly R; Gupta AK; Winter T; Zane LT; Vlahovic T
    J Drugs Dermatol; 2017 Oct; 16(10):1016-1021. PubMed ID: 29036255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.
    Toledo-Bahena ME; Bucko A; Ocampo-Candiani J; Herz-Ruelas ME; Jones TM; Jarratt MT; Pollak RA; Zane LT
    J Drugs Dermatol; 2014 Sep; 13(9):1124-32. PubMed ID: 25226015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies.
    Elewski BE; Aly R; Baldwin SL; González Soto RF; Rich P; Weisfeld M; Wiltz H; Zane LT; Pollak R
    J Am Acad Dermatol; 2015 Jul; 73(1):62-9. PubMed ID: 25956661
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.